参考文献/References:
[1] 《中国心血管健康与疾病报告2021》编写组. 《中国心血管健康与疾病报告2021》要点解读[J]. 中国心血管杂志,2022,27(4):305-318.
[2] Wang HY,Yuan Y,Tang C,et al. COVID-19 control in community hospitals:experience from four community hospitals in Beijing,China[J]. Inquiry ,2022,59:469580211055621.
[3] Hernesniemi JA,Mahdiani S,Tynkkynen JA,et al. Extensive phenotype data and machine learning in prediction of mortality in acute coronary syndrome—The MADDEC study[J]. Ann Med,2019,51(2):156-163.
[4] Motwani M,Dey D,Berman DS,et al. Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease:a 5-year multicentre prospective registry analysis[J]. Eur Heart J,2017,38(7):500-507.
[5] Alsharqi M,Upton R,Mumith A,et al. Artificial intelligence:a new clinical support tool for stress echocardiography[J]. Expert Rev Med Devices,2018,15(8):513-515.
[6] Liu J,Chen J,Wang HY. Arterial function should be focused in the follow-up treatment of COVID-19 mild patients[J]. J Cardiovasc Med Cardiol,2021,021-022.10.17352/2455-2976.000164.
[7] 陈捷,王宏宇. 新型冠状病毒肺炎患者心血管损伤机制研究进展[J]. 心血管病学进展,2021,42(5):401-403.
[8] 王宏宇. 血管病学[M]. 北京:人民军医出版社,2006:1-8.
[9] Saad NEA,Vedantham S,Gould JE. 血管于介入影像病例点评171例[M]. 徐瑞,李国华,王宏宇,译. 第2版. 北京:北京大学医学出版社,2013:189-280.
[10] 王宏宇. 推广血管健康理念,促进血管医学专业发展[J]. 中国循环杂志,2018,33(10):1026-1028.
[11] Creager MA,Beckman JA,Oscalzo JI. 血管医学(第2版)[M]. 王宏宇,译. 北京:北京大学医学出版社,2019:139-164.
[12] 王宏宇. 中国血管医学学科的形成与发展趋势[J]. 解放军医学杂志,2014,39(7):513-516.
[13] 中国血管病变早期检测技术标准化建议(草案)专家工作组. 中国血管病变早期检测技术标准化建议(草案) [ J]. 中国民康医学,2005,17(增刊):1-4.
[14] 王宏宇. 血管早期病变评价与血管健康维护[J]. 中华心血管病杂志,2007,35(10):964-965.
[15] 王宏宇. 血管医学:血管健康评价与血管疾病综合防治[J]. 中华医学杂志,2010,90(30):2092-2093.
[16] 王宏宇,刘欢. 推动心脏和血管健康规范化综合评估,增强全面血管健康意识——《中国血管健康评估系统应用指南(2018第三次报告)解读》[J]. 中华医学杂志,2018,98(37):2953-2954.
[17] 王宏宇. 血管医学精要[M]. 北京:北京大学医学出版社,2014:1-2.
[18] 王宏宇. 血管衰老临床检测技术—重视血管内皮功能的评价与EndoFIND研究启示[J].中国心血管杂志,2021,26(5):418-424.
[19] 王宏宇,刘金波. 血管医学:实践转化医学、全科医学及中西医结合治疗的主阵地[J]. 心血管病学进展,2012,33(2):145-146.
[20] Liu H,Wang H. Early detection system of vascular disease and its application prospect[J]. Biomed Res Int,2016,2016:1723485.
[21] 王宏宇,刘欢. 新的血管健康分级标准与血管医学[J]. 心血管病学进展,2015,36(4):365-368.
[22] 蒋姗彤,王宏宇. 基于北京血管健康分级指导的智能化全生命周期心脏和血管健康管理[J]. 中华临床医师杂志(电子版),2019,13(11):868-871.
[23] Liu H,Zhou X,Liu J,et al. Rationale and design of the application value of Beijing Vascular Health Stratification(BVHS):predictive value of combined assessment of vascular structure and function for cardiovascular events in general Chinese population[J]. BMC Cardiovasc Disord,2021,21(1):498.
[24] Liu H,Liu JB,Zhao HW,et al. The design and rationale of the Beijing Vascular Disease Patients Evaluation Study(BEST study)[J]. Contemp Clin Trials Commun,2017,7:18-22.
[25] 刘欢,何映东,刘金波,等. 血管健康指标对新发心脑血管事件的预测价值:北京血管健康分级标准的初步验证[J]. 北京大学学报(医学版),2020,52(3):514-520.
[26] 中国血栓性疾病防治指南专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志,2018,98(36):2861-2888.
[27] 中国痴呆与认知障碍诊治指南写作组. 中国阿尔兹海默病一级预防指南[J]. 中华医学杂志,2020,100(35):2721-2735.
[28] 中国医药教育协会血管医学专业委员会,中华医学会北京心血管病学分会血管专业学组,北京大学医学部血管疾病社区防治中心. 中国血管健康评估系统应用指南(2018第三次报告) [ J]. 中华医学杂志,2018,98(37):2955-2967.
[29] 王宏宇. 北京大学血管医学临床诊疗常规[M]. 北京:北京大学医学出版社,2021:37-70.
[30] 刘欢,刘润冬,王宏宇. 血管内皮功能的评价及其临床价值[J]. 心血管病学进展,2016,37(4):426-430.
[31] 东條 美奈子. 血管内皮功能诊断[M]. 王宏宇,译. 北京:北京大学医学出版社,2020:21-28.
[32] Liu H,Xie G,Huang W,et al. Rationale and design of a multicenter,randomized,patients-blinded two-stage clinical trial on effects of endothelial function test in patients with non-obstructive coronary artery disease(ENDOFIND)[J]. Int J Cardiol,2021,325:16-22.
[33] Lan Y,Liu H,Liu J,et al. The relationship between serum bilirubin levels and peripheral arterial disease and gender difference in patients with hypertension:BEST study[J]. Angiology,2020,71(4):340-348.
[34] 刘欢,王宏宇,刘金波,等. 颈动脉斑块患者大动脉功能与冠心病和下肢动脉疾病的关系[J].北京大学学报(医学版),2017,49(6):1027-1033.
[35] 洪永强,王宏宇,郑长业,等. 畲族自然人群脉压与双侧颈动脉血管功能的关联研究[J]. 中华流行病学杂志,2010,31(6):688-691.
[36] Liu H,Liu J,Huang W,et al. Association between multi-site atherosclerotic plaques and systemic arteriosclerosis:results from the BEST study(Beijing Vascular Disease Patients Evaluation Study)[J]. Cardiovasc Ultrasound,2020,18(1):30.
[37] Liu H,Xie W,Liu J,et al. Comparison of vascular-related diseases in their associations with carotid femoral pulse wave velocity:from the Beijing Vascular Disease Patients Evaluation Study(BEST Study)[J]. Int J Clin Pract,2019,73(11):e13400.
[38] Liu J,Wang K,Liu H,et al. Cross-sectional relationship between carotid-femoral pulse wave velocity and biomarkers in vascular-related diseases[J]. Int J Hypertens,2020,2020:6578731.
[39] Zhao XX,Liu JB,Zhao HW,et al. Cardio-ankle vascular index value in dyslipidemia patients affected by cardiovascular risk factors[J]. Clin Exp Hypertens,2018,40(4):312-317.
[40] Wang HY. Cardio-ankle vascular index:a new marker for vascular health evaluation(experience from China)[J]. J Hum Hypertens,2015,29(2):136.
[41] Liu J,Liu H,Zhao H,et al. Descriptive study of relationship between cardio-ankle vascular index and biomarkers in vascular-related diseases[J]. Clin Exp Hypertens,2017,39(5):468-472.
[42] Liu H,Liu J,Zhao H,et al. Association of brain white matter lesions with arterial stiffness assessed by cardio-ankle vascular index. The Beijing Vascular Disease Evaluation STudy(BEST)[J]. Brain Imaging Behav,2021,15(2):1025-1032.
[43] 王宏宇. 血压变异性与靶器官保护[J]. 心血管病学进展,2011,32(1):34-36.
[44] 王宏宇. 家庭自测血压和动态血压的应用[J]. 心血管病学进展,2011,32(2):158-159.
[45] Li C,Ma Y,Hua R,et al. Dose-response relationship between long-term blood pressure variability and cognitive decline[J]. Stroke,2021,52(10):3249-3257.
[46] Liu H,Liu JB,Zhao HW,et al. Relationship between serum uric acid and vascular function and structure markers and gender difference in a real-world population of China—From Beijing Vascular Disease Patients Evaluation Study(BEST) Study[J]. J Atheroscler Thromb,2018,25(3):254-261.
[47] Liu J,Wang K,Liu H,et al. Relationship between carotid-femoral pulse wave velocity and uric acid in subjects with hypertension and hyperuricemia[J]. Endocr J,2019,66(7):629-636.
[48] Liu H,Liu J,Zhao H,et al. Relationship between glycated hemoglobin and low Ankle-Brachial Index:a cross-sectional observational study from the Beijing Vascular Disease Evaluation Study(BEST Study)[J]. Int Angiol,2019,38(6):502-507.
[49] 郭晓玲,吴浩,刘新颖,等. 智慧家庭医生优化协同模式的构建与实现[J]. 中国全科医学,2017,20(7):784-788.
[50] 王宏宇,Lerman A. 非传统血管健康危险因素管理策略—2019专家观点[M]. 北京:北京大学医学出版社,2020:4-29.
[51] 中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中国循环杂志,2019,34(1):4-28.
[52] 吴浩, 刘新颖, 张世红,?等. “互联网+社区卫生健康管理服务” 标准化建设指南(二期) [J]. 中国全科医学,2018,21(16):1891-1909.
[53] 尹李虎,王宏宇. 中医“治未病”理论与血管疾病早期预防[J]. 中国中医基础医学,2012,18(7):793-795.
[54] Liu H,Huang W,Liu J,et al. Association between arteriosclerosis and uncontrolled blood pressure in patients with essential hypertension:cross-sectional observational study results of the BEST Study[J]. J Vasc Res,2022,59(3):189-198.
[55] 张颖怡,刘金波,刘欢,等. 全身动脉粥样硬化与脑梗死的关系:北京血管病变评价研究结果[J]. 心血管病学进展,2021,42(3):277-284.
[56] 文芳,王宏宇. 阻塞性睡眠呼吸暂停与心血管相关疾病的关系研究进展[J]. 心血管病学进展,2021,42(4):302-305.
[57] Barnes JN,Pearson AG,Corkery AT. Exercise,arterial stiffness,and cerebral vascular function:partential impact on brain health[J]. J Int Neuropsychol Soc,2021,27(8):761-775.
[58] Dupont JJ,Kenney RM,Patel AR,et al. Sex difference in mechanisms of arterial stiffness[J]. Br J Pharmacol,2019,176(21):4208-4225.
[59] 王宏宇,陈新. 依托信息化的全生命周期血管健康管理与心血管疾病社区防治策略[J]. 中国临床医师,2020,22(9):1281-1284.
[60] Wen F,Liu Y,Wang H. Clinical evaluation tool for vascular health–Endothelial function and cardiovascular disease management[J]. Cells,2022,11(21):3363.
[61] Lloyd-Jones DM,Braun LT,Ndumele CE,et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease:a special report from the American Heart Association and American College of Cardiology[J]. J Am Coll Cardiol,2019,73(24):3153-3167.
[62] Javaid A,Zghyer F,Kim C,et al. Medicine 2032:the future of cardiovascular disease prevention with machine learning and digital health technology[J]. Am J Prev Cardiol,2022,12:100379.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(1):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(1):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(1):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]